Ambu and Medical Advisory Fuel Medical Group Announce Partnership

June 30, 2020

Ambu Inc., a rapidly growing pioneer of sterile, single-use medical devices, and Fuel Medical Group, the leading business advisory resource for ENTs, audiologists, otologists, and universities, have entered into a partnership the companies announced today.

Under the agreement, Ambu will offer Fuel Medical entrée to a broad hospital market for services, including marketing, finance, digital strategies, professional development, and recruiting as well as advising practices on maximizing revenue and streamlining administrative operations.

In turn, Fuel Medical, which is based in Camas, Washington, will broaden Ambu’s reach into medical practices by offering an array of state-of-the-art, single-use endoscopes that include rhinolaryngoscopes, bronchoscopes, duodenoscopes, and advanced monitors that increase safety and efficiency.

“This is a perfect match that will enable both companies to expand their reach into new and growing markets,” said Juan Jose Gonzalez, CEO of Ambu A/S. “Fuel Medical has such a strong reputation as a leader in a business advisory that it was difficult to overlook their success. We are thrilled with the partnership and see an incredibly productive future.”

“We couldn’t be more excited about this partnership as we both believe in each other’s missions,” added Brendan Ford, Fuel Medical Group’s Co-Founder. “We have a lot of overlap in our goals, specifically when it comes to innovative ideas and building lasting relationships with our customers.”

Shawn Parker, Fuel Medical Group’s Co-Founder, said “Single-use scopes are ideal for ENT practices as they provide tremendous value due to their sanitary nature. If we can offer safer products to our members, we can help them provide exceptional care to their patients.”

Specifics about the deal were not disclosed.

SourceAmbu

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”